Serum biomarkers and clinical outcomes in heart failure patients treated de novo with carvedilol
Nessler, Jadwiga ; Nessler, Bohdan ; Golebiowska-Wiatrak, Renata ; Palka, Ilona ; Gackowski, Andrzej ; Kitlinski, Mariusz LU ; Melander, Olle LU
and Fedorowski, Artur
LU
(2013)
In Cardiology Journal
20(2).
p.144-151
- Abstract
- Background: The role of inflammatory and hemodynamic stress biomarkers in heart failure (HF) patients treated de novo with beta-blockers has been poorly studied. Methods: A total of 86 patients (age 56 +/- 9 years, 81 men) with left ventricular ejection fraction (LVEF) < 40% and previously not treated with beta-blockers were initiated on carvedilol. At baseline and 12 months later we performed echocardiography, cardiopulmonary exercise testing, and determined serum levels of B-type natriuretic peptide (BNP), endothelin-1 (ET-1), C-reactive protein (CRP), interleukin-6, and tumor necrosis factor alpha (TNF-alpha). Patients were followed up over a total period of 9 +/- 3 years from baseline. Results: Increased baseline CRP and its... (More)
- Background: The role of inflammatory and hemodynamic stress biomarkers in heart failure (HF) patients treated de novo with beta-blockers has been poorly studied. Methods: A total of 86 patients (age 56 +/- 9 years, 81 men) with left ventricular ejection fraction (LVEF) < 40% and previously not treated with beta-blockers were initiated on carvedilol. At baseline and 12 months later we performed echocardiography, cardiopulmonary exercise testing, and determined serum levels of B-type natriuretic peptide (BNP), endothelin-1 (ET-1), C-reactive protein (CRP), interleukin-6, and tumor necrosis factor alpha (TNF-alpha). Patients were followed up over a total period of 9 +/- 3 years from baseline. Results: Increased baseline CRP and its on-treatment decrease were associated with improvement of LVEF (est. coefficient per one SD: 1.6; 95% CI: -0.05,3.28; p = 0.056, and -1.80; -3.43, -0.18; p = 0.030, respectively) and diminishing of LV end-systolic volume index [mL/m(2)] (-6.83; -11.32; -2.34; p = 0.003, and 5.85; 1.23; -10.46; p = 0.014, respectively). Higher baseline ET-1 and on-treatment increase in TNF-alpha predicted frequent admissions (>1) for cardiac complications (odds ratio per one SD: 1.98; 95% CI: 1.09-3.59; p = 0.025, and 2.07, 1.12-3.84, p = 0.021, respectively) whereas higher baseline BNP was asociated with increased mortality (hazard ratio per one SD: 2.09, 95% CI: 1.26-3.45; p = 0.004). Conclusions: Serum biomarkers may have different roles in prediction of clinical outcomes among HF patients treated de novo with carvedilol. (Cardiol J 2013; 20, 2: 144-151) (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3748211
- author
- Nessler, Jadwiga
; Nessler, Bohdan
; Golebiowska-Wiatrak, Renata
; Palka, Ilona
; Gackowski, Andrzej
; Kitlinski, Mariusz
LU
; Melander, Olle
LU
and Fedorowski, Artur
LU
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- heart failure, beta-blocker, biological markers, natriuretic peptides, endothelin-1, C-reactive protein
- in
- Cardiology Journal
- volume
- 20
- issue
- 2
- pages
- 144 - 151
- publisher
- Via Medica
- external identifiers
-
- wos:000317125000007
- scopus:84885217666
- ISSN
- 1898-018X
- DOI
- 10.5603/CJ.2013.0027
- language
- English
- LU publication?
- yes
- id
- 5a19918f-2464-467f-a6ef-64de90c520f2 (old id 3748211)
- date added to LUP
- 2016-04-01 11:07:35
- date last changed
- 2024-01-07 08:57:31
@article{5a19918f-2464-467f-a6ef-64de90c520f2,
abstract = {{Background: The role of inflammatory and hemodynamic stress biomarkers in heart failure (HF) patients treated de novo with beta-blockers has been poorly studied. Methods: A total of 86 patients (age 56 +/- 9 years, 81 men) with left ventricular ejection fraction (LVEF) < 40% and previously not treated with beta-blockers were initiated on carvedilol. At baseline and 12 months later we performed echocardiography, cardiopulmonary exercise testing, and determined serum levels of B-type natriuretic peptide (BNP), endothelin-1 (ET-1), C-reactive protein (CRP), interleukin-6, and tumor necrosis factor alpha (TNF-alpha). Patients were followed up over a total period of 9 +/- 3 years from baseline. Results: Increased baseline CRP and its on-treatment decrease were associated with improvement of LVEF (est. coefficient per one SD: 1.6; 95% CI: -0.05,3.28; p = 0.056, and -1.80; -3.43, -0.18; p = 0.030, respectively) and diminishing of LV end-systolic volume index [mL/m(2)] (-6.83; -11.32; -2.34; p = 0.003, and 5.85; 1.23; -10.46; p = 0.014, respectively). Higher baseline ET-1 and on-treatment increase in TNF-alpha predicted frequent admissions (>1) for cardiac complications (odds ratio per one SD: 1.98; 95% CI: 1.09-3.59; p = 0.025, and 2.07, 1.12-3.84, p = 0.021, respectively) whereas higher baseline BNP was asociated with increased mortality (hazard ratio per one SD: 2.09, 95% CI: 1.26-3.45; p = 0.004). Conclusions: Serum biomarkers may have different roles in prediction of clinical outcomes among HF patients treated de novo with carvedilol. (Cardiol J 2013; 20, 2: 144-151)}},
author = {{Nessler, Jadwiga and Nessler, Bohdan and Golebiowska-Wiatrak, Renata and Palka, Ilona and Gackowski, Andrzej and Kitlinski, Mariusz and Melander, Olle and Fedorowski, Artur}},
issn = {{1898-018X}},
keywords = {{heart failure; beta-blocker; biological markers; natriuretic peptides; endothelin-1; C-reactive protein}},
language = {{eng}},
number = {{2}},
pages = {{144--151}},
publisher = {{Via Medica}},
series = {{Cardiology Journal}},
title = {{Serum biomarkers and clinical outcomes in heart failure patients treated de novo with carvedilol}},
url = {{http://dx.doi.org/10.5603/CJ.2013.0027}},
doi = {{10.5603/CJ.2013.0027}},
volume = {{20}},
year = {{2013}},
}